Overview

  • Product name
    Anti-VEGF Receptor 2 antibody
    See all VEGF Receptor 2 primary antibodies
  • Description
    Goat polyclonal to VEGF Receptor 2
  • Host species
    Goat
  • Specificity
    Based on immunoblotting and ELISA, this antibody shows approximately 2% cross-reactivity with recombinant mouse VEGF Receptor 1, and no cross-reactivity with recombinant human VEGF Receptor 1 and VEGF Receptor 3.
  • Tested applications
    Suitable for: ICC/IF, Indirect ELISA, IHC-P, Flow Cyt, ICC, WB, Neutralising, Blockingmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Dog
    Does not react with: Human
  • Immunogen

    Recombinant fragment from the extracellular domain (Mouse) expressed in mouse NSO cells.

  • General notes
    Do not store in frost-free freezer. Endotoxin level is < 10 ng/mg antibody as determined by the LAL (Limulus amebocyte lysate) method.

Applications

Our Abpromise guarantee covers the use of ab10972 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF Use a concentration of 5 - 15 µg/ml. (and tissues).
Indirect ELISA Use a concentration of 0.5 - 1 µg/ml.
IHC-P Use at an assay dependent concentration. PubMed: 20882677
Flow Cyt Use a concentration of 3 - 10 µg/ml.

ab37373 - Goat polyclonal IgG, is suitable for use as an isotype control with this antibody.

ICC Use at an assay dependent concentration. See Abreview.
WB Use a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 152 kDa.
Neutralising Use at an assay dependent concentration.
Blocking Use at an assay dependent concentration. PubMed: 20884890

Target

  • Function
    Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
  • Involvement in disease
    Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
  • Sequence similarities
    Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
    Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications
    Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
  • Cellular localization
    Membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • CD309 antibody
    • CD309 antigen antibody
    • EC 2.7.10.1 antibody
    • Fetal liver kinase 1 antibody
    • FLK-1 antibody
    • FLK1 antibody
    • FLK1, mouse, homolog of antibody
    • Kdr antibody
    • Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody
    • Kinase insert domain receptor antibody
    • KRD1 antibody
    • Ly73 antibody
    • Protein tyrosine kinase receptor FLK1 antibody
    • Protein-tyrosine kinase receptor flk-1 antibody
    • soluble VEGFR2 antibody
    • Tyrosine kinase growth factor receptor antibody
    • Vascular endothelial growth factor receptor 2 antibody
    • VEGFR 2 antibody
    • VEGFR antibody
    • VEGFR-2 antibody
    • VEGFR2 antibody
    • VGFR2_HUMAN antibody
    see all

Images

  • Ab10972 positively staining VEGF receptor 2 in paraformaldehyde fixed mouse retinal pigment epithelium (10 µg/ml). Used in conjunction with donkey anti goat IgG (Alexa ® 488) at 1/100.

    This image is courtesy of an Abreview submitted on 12th October 2005. We do not have any further information relating to this image.

References

This product has been referenced in:
  • Shen M  et al. Xanthatin inhibits corneal neovascularization by inhibiting the VEGFR2-mediated STAT3/PI3K/Akt signaling pathway. Int J Mol Med 42:769-778 (2018). Read more (PubMed: 29717775) »
  • Wang TC  et al. Characterization of highly proliferative secondary tumor clusters along host blood vessels in malignant glioma. Mol Med Rep 12:6435-44 (2015). IHC-Fr ; Rat . Read more (PubMed: 26299849) »
See all 8 Publications for this product

Customer reviews and Q&As

Filter by Application

Filter by Species

Filter by Ratings

1-7 of 7 Abreviews

Application
Western blot
Sample
Human Cell lysate - whole cell (A549)
Loading amount
20 µg
Specification
A549
Treatment
TRAIL
Gel Running Conditions
Reduced Denaturing (12.5% SDS-PAGE)
Blocking step
(agent) for 2 hour(s) and 0 minute(s) · Concentration: 100% · Temperature: 20°C

Abcam user community

Verified customer

Submitted Apr 02 2012

Application
Immunocytochemistry/ Immunofluorescence
Sample
Human Cell (MCF-7)
Specification
MCF-7
Fixative
Paraformaldehyde
Permeabilization
Yes - 0.1% Triton-X-100
Blocking step
Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 2% · Temperature: 22°C

Abcam user community

Verified customer

Submitted Jun 04 2008

Application
Immunocytochemistry
Sample
Human Cell (retinal pigment epithelium)
Specification
retinal pigment epithelium
Fixative
Paraformaldehyde
Blocking step
BSA as blocking agent for 30 minute(s) · Concentration: 5%

Abcam user community

Verified customer

Submitted Feb 20 2008

Abcam has not validated the combination of species/application used in this Abreview.
Application
Western blot
Sample
Human Cell lysate - whole cell (HUVEC)
Loading amount
10 µg
Specification
HUVEC
Treatment
With or without VEGF
Gel Running Conditions
Reduced Denaturing
Blocking step
Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C

Abcam user community

Verified customer

Submitted Feb 20 2008

Abcam guarantees this product to work in the species/application used in this Abreview.
Application
Immunocytochemistry
Sample
Dog Cell (Kidney Epithelial Cell)
Specification
Kidney Epithelial Cell
Fixative
Paraformaldehyde
Blocking step
BSA as blocking agent for 30 minute(s) · Concentration: 5%

Abcam user community

Verified customer

Submitted Oct 14 2005

Abcam guarantees this product to work in the species/application used in this Abreview.
Application
Immunocytochemistry
Sample
Rat Cell (dermal epithelium)
Specification
dermal epithelium
Fixative
Paraformaldehyde
Blocking step
BSA as blocking agent for 30 minute(s) · Concentration: 5%

Abcam user community

Verified customer

Submitted Oct 14 2005

Abcam guarantees this product to work in the species/application used in this Abreview.
Application
Immunocytochemistry
Sample
Mouse Cell (retinal pigment epithelium)
Specification
retinal pigment epithelium
Fixative
Paraformaldehyde
Blocking step
BSA as blocking agent for 30 minute(s) · Concentration: 5%

Abcam user community

Verified customer

Submitted Oct 12 2005

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up